Using PU.1 and Jun dimerization protein 2 transcription factor expression in myelodysplastic syndromes to predict treatment response and leukaemia transformation

Ann Hematol. 2019 Jun;98(6):1529-1531. doi: 10.1007/s00277-019-03627-9. Epub 2019 Feb 5.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antimetabolites, Antineoplastic / pharmacology
  • Antimetabolites, Antineoplastic / therapeutic use
  • Azacitidine / pharmacology
  • Azacitidine / therapeutic use
  • Biomarkers
  • Biomarkers, Tumor
  • Bone Marrow / metabolism
  • Bone Marrow / pathology
  • Cell Transformation, Neoplastic / genetics
  • DNA Methylation / drug effects
  • Disease Progression
  • Down-Regulation
  • Gene Expression Regulation, Neoplastic* / drug effects
  • Humans
  • Leukemia, Myeloid, Acute / genetics
  • Leukemia, Myeloid, Acute / metabolism
  • Myelodysplastic Syndromes / drug therapy
  • Myelodysplastic Syndromes / genetics*
  • Myelodysplastic Syndromes / metabolism
  • Myelodysplastic Syndromes / physiopathology
  • Prognosis
  • Proto-Oncogene Proteins / biosynthesis*
  • Proto-Oncogene Proteins / genetics
  • Repressor Proteins / biosynthesis*
  • Repressor Proteins / genetics
  • Trans-Activators / biosynthesis*
  • Trans-Activators / genetics
  • Up-Regulation / drug effects

Substances

  • Antimetabolites, Antineoplastic
  • Biomarkers
  • Biomarkers, Tumor
  • JDP2 protein, human
  • Proto-Oncogene Proteins
  • Repressor Proteins
  • Trans-Activators
  • proto-oncogene protein Spi-1
  • Azacitidine

Grants and funding